CHEMOTHERAPY-INDUCED BONE MARROW TOXICITY: MECHANISMS, CLINICAL IMPACT, AND MODERN PROTECTIVE STRATEGIES
Article Sidebar
Main Article Content
Abstract:
Chemotherapy remains the backbone of systemic cancer therapy, but its non-selective cytotoxicity causes significant hematologic toxicity. Bone marrow suppression (myelosuppression) is among the most common and dose-limiting side effects, leading to anemia, leukopenia, and thrombocytopenia. This paper reviews the molecular mechanisms, clinical implications, and recent advances in preventing chemotherapy-induced bone marrow injury. Particular focus is given to hematopoietic stem cell (HSC) depletion, stromal niche disruption, and novel therapeutic strategies such as growth factor therapy, targeted delivery, and stem cell transplantation.
Article Details
How to Cite:
References:
Saini, P., et al. (2023). Hematologic toxicities in cancer chemotherapy: Current trends and management strategies. Oncology Reviews, 17(1), 48–62. DOI: 10.4081/oncol.2023.487
Zhang, Q., et al. (2024). NF-κB–mediated inflammation in chemotherapy-induced bone marrow suppression. Frontiers in Immunology, 15:12852. DOI: 10.3389/fimmu.2024.012852
Eissa, H., et al. (2023). Incidence and risk factors of myelosuppression in solid tumor chemotherapy. Journal of Cancer Research, 149(5), 820–831.
Kim, Y., et al. (2022). Efficacy of G-CSF in prevention of neutropenia among breast cancer patients receiving chemotherapy. Clinical Oncology, 34(7), 611–620.
Li, X., et al. (2023). Nanocarrier-based drug delivery for reduced bone marrow toxicity in cancer therapy. Advanced Therapeutics, 6(2):2200121.
Chen, J., et al. (2024). Mesenchymal stem cell therapy for hematopoietic recovery after chemotherapy. Stem Cell Research, 78:102295.